aTyr Pharma (ATYR) announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The Company expects to report topline results from this study in the third quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
- Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
- aTyr Pharma to be added to Russell 2000, Russell 3000 Indices
- aTyr Pharma price target raised to $25 from $17 at Wells Fargo
- Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence